Please join our staff as we participate or present in the following oral and poster presentations at the 2017 ASCO Annual Meeting
Sunday, June 4
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
8:00 AM – 11:30 AM
Location: Hall A
POSTER SESSION: Breast Cancer—Local/Regional/Adjuvant
Abstract 521:SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy
Poster Board: #121
G. Thomas Budd, MD – First Author
8:00 AM – 11:30 AM
Location: Hall A
POSTER SESSION: Genitourinary (Nonprostate) Cancer
Abstract 4529: Molecular profiling of small cell bladder cancer (SCBC) to reveal gene expression determinants of an aggressive phenotype
Poster Board: #207
Vadim S. Koshkin, MD – First Author
Abstract 4534: Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape
Poster Board: #212
Petros Grivas, MD, PhD – First Author
Abstract 4548: Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC)
Poster Board: #226
Moshe Chaim Ornstein, MD, MA – First Author
Abstract 4584: Sunitinib in patients with metastatic renal cell carcinoma: Clinical outcome according to IMDC risk group
Poster Board: #262
Brian I. Rini, MD – First Author
Abstract 4586: Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis
Poster Board: #264
Vadim S. Koshkin, MD – First Author
Abstract 4587: T cell infiltration (TCI) in matched renal biopsy (bx) and nephrectomy (nx) samples in renal cell carcinoma (RCC).
Poster Board: #265
Haris Zahoor, MD – First Author
Abstract TPS4597: Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC)
Poster Board: #271b
Brian I. Rini, MD – First Author
Abstract TPS4600: Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
Poster Board: #273a
Brian I. Rini, MD – First Author
8:00 AM – 11:30 AM
Location: Hall A
POSTER SESSION: Sarcoma
Abstract TPS11079: A bi-shRNAfurin and GMCSF engineered autologous tumor cell immunotherapy vs. gemcitabine + docetaxel for Ewing sarcoma and with cryoablation in Ewing family tumors
Poster Board: #402a
Peter Meade Anderson, MD, PhD – First Author
4:45 PM – 6:00 PM
Location: E354b
EDUCATION SESSION: Turning the On-Off Dial: Cancer Epigenetics and Therapy
5:25 PM – 5:45 PM
Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer?
Yogen Saunthararajah, MD – Speaker
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust